Sab Biotherapeutics, Inc. (SABSW) — 10-Q Filings
All 10-Q filings from Sab Biotherapeutics, Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
SAB Biotherapeutics Swings to Profit on Warrant Revaluation, PIPE Infusion
— Nov 14, 2025 Risk: medium
SAB Biotherapeutics, Inc. reported a significant financial turnaround for the nine months ended September 30, 2025, achieving a net income of $30,134,426, a sub -
SAB Biotherapeutics' Q2 Loss Widens on Grant Revenue Drop
— Aug 7, 2025 Risk: high
SAB Biotherapeutics, Inc. reported a net loss of $10.5 million for the three months ended June 30, 2025, a significant increase from the $8.2 million net loss i -
SAB Biotherapeutics Files Q1 2025 10-Q
— May 9, 2025 Risk: medium
SAB Biotherapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Big Cypress Acquisition Corp., reported on its fin -
SAB Biotherapeutics Q3 2024: Grant Revenue and Warrant Details
— Nov 6, 2024 Risk: medium
SAB Biotherapeutics, Inc. filed its Q3 2024 10-Q report on November 6, 2024. The company, formerly Big Cypress Acquisition Corp., reported grant revenue of $0.1 -
SAB Biotherapeutics Files Q2 2024 10-Q Report
— Aug 8, 2024 Risk: medium
SAB Biotherapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as Big Cypress Acquisition Corp., reported on its fina -
SAB Biotherapeutics Reports Q1 Grant Revenue, Details Warrant Activity
— May 20, 2024 Risk: high
SAB Biotherapeutics, Inc. filed its 10-Q for the period ending March 31, 2024. The company reported grant revenue of $0.1 million for the three months ended Mar
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX